Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.

Mike Trujillo believed he had found a cure for his condition when he went for stem cell treatment. He couldn't have been more ...

RIT biomedical engineering researchers identify a protein that can reduce fibrosis and slow disease progression.

Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026Obtained alignment with FDA and ...

Kidney damage can sneak up on people without symptoms. A new diagnosis can mean major limits on how a person lives ...

Veteran journalist Oren Nahari revealed he has ALS, a severe degenerative neurological disease. How many Israelis are ...

Researchers at Case Western Reserve University found evidence that gut bacteria may contribute to brain damage in Amyotrophic ...

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people ...

Frontotemporal dementia (FTD), in particular, may be at play, and identifying ways to slow down its progression can help. In ...

The Greenport FD’s loss of authorization to provide advanced life support care has raised questions among North Fork ...

A protein long studied for its role in amyotrophic lateral sclerosis and frontotemporal dementia now appears to serve a ...